## **Refine Search**

## Search Results -


Terms	Documents
L3 and (concentric)	11

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database


Database:

EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins

Search:







## Search History

DATE: Monday, May 14, 2007 Purge Queries Printable Copy Create Case

Set Name Query side by side			Set Name result set
DB=PC	GPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES; OP=OR		
<u>L5</u>	L3 and (concentric)	11	<u>L5</u>
<u>L4</u>	L3 and 424/450.ccls.	21	<u>L4</u>
<u>L3</u>	L2 and (vaccine or antigen)	116	<u>L3</u>
<u>L2</u>	multilamellar same (liquid adj2 crystalline)	190	<u>L2</u>
<u>L1</u>	multilamellar same (liquid adj2 crystalline) same (vaccine or antigen)	1	L1

END OF SEARCH HISTORY

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Cenerate Collection 🚧 Print

L4: Entry 9 of 21

File: USPT

Sep 4, 2001

DOCUMENT-IDENTIFIER: US 6284267 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Amphiphilic materials and liposome formulations thereof

## Brief Summary Text (6):

Liposomes are spherical vesicles of self-closed hydrated bilayers of amphiphilic lipids surrounding a generally central inner aqueous phase core which can differ in composition from the extraliposomal aqueous medium (Bangham and Horne, 1964). The lipid chains may be liquid-crystalline or solid-like gel phases. Liposomes are colloidal particles ranging in diameter from 20 nm to 5000 nm. Depending on the size and the number of constituent lamellar layers, these are classified as small or large unilamellar vesicles, and as multilamellar vesicles. The multilamellar vesicles have additional water layers trapped adjacent to the hydrophilic ends (polar head groups) between the regular dual arrays of the lipophilic (hydrophobic) alkyl chains (fatty tails).

#### Brief Summary Text (24):

The unique interfacial topography makes these novel amphiphilic materials and the derived self-assembled aggregates particularly appropriate for application in liposomal and micellar preparations suitable for passive and targeted drug delivery and antigen-presentation for diagnostics. The unique topography may be engendered additionally by equilibrating the hydrated novel amphiphiles with preformed liposomes and biological cells to create non-immunogenic red blood cells for blood substitutes and analogous biomaterials.

## Brief Summary Text (57):

In further embodiments, the hydrophilic compound may further comprise a selected agent attached at a site distinct from said at least two hydrophobic moieties. Exemplary agents that may be attached in this manner are antibodies and antigens against which one desires to raise a humoral or cellular immune response. Other appropriate molecules are ligands for biological receptors, or in reciprocal embodiments, one or more biological receptor molecules.

#### Brief Summary Text (63):

Again, the resultant liposome may be advantageously combined with other surface-available components, such that the liposome comprises at least one surface-available antibody, <u>antigen</u> or binding ligand dispersed in the liposome bilayer or tethered to a component of the liposome bilayer.

#### Brief Summary Text (66):

The liposomes of the invention may be formulated with any one or more of the lipid components known to those of ordinary skill in the art. By way of example only, one may mention phospholipids, such as phosphatidylcholine; sterols, such as cholesterol, sphingolipids, such as sphingomyelin; and other components such as sucrose. By means of an exemplary embodiment only, the amphiphile-containing liposomes of the invention may contain the following constituents: between about 40 mole % and about 60 mole % amphiphile; between about 20 mole % and about 30 mole % of phosphatidylcholine; between about 5 mole % and about 10 mole % of sphingomyelin; with the optional addition of other components such as gangliosides and sucrose. Again, the liposomes may comprise in their outer bilayer one or more

surface-available components such as antibodies, <u>antigens</u>, binding ligands, receptors, or functional portions thereof. These components may be dispersed within the bilayer or covalently attached to a component thereof.

#### Brief Summary Text (68):

The type of selected agent that may be functionally associated with the liposomes of the invention is virtually limitless and those of skill in the art are referred to exemplary Tables 3A, 3B and 4. By way of example only, one may mention selected pharmacological agents, such as chemotherapeutic agents or cytotoxins (Table 3B); agents to combat infectious organisms, such as antibiotics, anti-virals and fungicides, particularly amphotericin B; immunological components, such as antibodies or fragments thereof, antigens, cytokines and anti-inflammatory agents in general; enzymes, hormones and neurotransmitters, anesthetics; blood components such as hemoglobin and coagulants; and a variety of nucleic acid molecules, constructs or vectors, including those that express any of the foregoing components and those that include antisense nucleic acids and ribozymes.

#### Drawing Description Text (9):

FIG. 7. Illustrative Biopodal Amphiphile Structures. Y=O, S, SS, NH, .dbd.N, HN (C .dbd.O), N-Alkyl, N,N-Dialkyl, N,N,N-Trialkylammonium, O(C.dbd.O), O(C.dbd.O)N, OP(.dbd.O)O.sub.2, and equivalent bond types. X=Reactive residue or linker for conjugation to <a href="mailto:antigens">antigens</a>, antibodies, biotin, chelators, receptor-mimics, and analogues.

#### <u>Drawing Description Text</u> (10):

FIG. 8. Illustrative Tripodal Amphiphile Structures. X=Reactive residue or linker for conjugation to <u>antigens</u>, antibodies, biotin, chelators, receptor-mimics, and analogues.

## <u>Detailed Description Text</u> (6):

The novel structural class of amphiphiles of the claimed invention represents a radical departure from existing structural motifs. Additionally, this molecular design engenders enhanced bilayer stability and unique topography of the liposomal surface barrier. Together, these attributes will result in increases, and even dramatic increases, in liposome blood circulation half-life. The novel amphiphiles may also be employed as functional components of other types of drug delivery vehicles. In fact, the unique structural and physicochemical properties of the disclosed amphiphiles render them useful in various biomedical applications and for use as blood substitutes, parenteral nutritional fat emulsions, antigen-presenting vehicles in diagnostics, and in skin and other personal care consumer products.

#### Detailed Description Text (12):

Several illustrative structures are shown in FIG. 7 and FIG. 8. These incorporate glycerol or pentaerythritol residues either as polymer branching points for providing functional groups within the polymer residue, or for attaching multiple lipid residues. Branching or multiple functional groups within the polymer may be provided by polyols and their block polymers, by hydroxy- and amino acids and peptides. The functional groups may be attached directly or via linkers/spacer residues to antigens, antibodies and other pendant ligands.

## <u>Detailed Description Text</u> (23):

For certain applications, for instance in transfection and gene delivery vehicles, oligomeric or polymeric residues such as spermidine, spermine, polylysine, and related polyamine, polyethyleneamine, and polycationic materials are useful. Polypeptide residues are useful as mimics for cell membrane anchored receptors, and as <a href="mailto:antiqens">antiqens</a> in diagnostics, and polyamino/cationic peptides for lung-surfactant replacement.

## <u>Detailed Description Text</u> (37):

Hydrophilic polymers with more than two hydroxyl groups may be utilized for the

synthesis of the polypodal novel amphiphiles exactly as described for the bipodals. Synthesis as in EXAMPLE 1 through EXAMPLE 5 may be performed with an excess of the lipid to conjugate all hydroxyls, or alternatively, with a limited molar proportion of the lipid to generate a mixture of products with two or more lipid conjugands and one or more free hydroxyls. The latter are used as loci for attaching antigens, antibodies and like moieties, or additional pendant polymer residues, usually after replacement with more reactive residues such as thiol, or derivatization to an activated group, with or without a spacer or linker residue. The same type of chemistry is utilized also for linking the hydrophilic polymer to lipid moieties with intervening spacer residues.

#### Detailed Description Text (49):

The packing arrangements are dictated by the geometrical space requirements of the hydrated head groups and the fattyacyl hydrocarbon chains. The difattyacyl chain glycerophospholipids normally form lamellar bilayers. The crystal and the lyotropic phase structure and behavior of phospholipids, and methods for their study have been described in detail (Shipley, 1986; incorporated herein by reference). Lamellar bilayers above the hydrocarbon chain melting transition temperature (gelto-liquid crystalline transition) on dilution with excess water and input of (mechanical) energy form the closed-end lamellar vesicles entrapping a part of the aqueous phase in the interior core forming liposomes. Liposomes may incorporate many bilayers (multilamellar; MLV)) or a single bilayer (unilamellar: ULV). The latter may be of small diameter and size (SUV) or relatively large (LUV) structures.

#### Detailed Description Text (58):

The novel structural class of amphiphiles of the claimed invention represents a radical departure from the existing structural motifs. Additionally, this molecular design engenders enhanced bilayer stability and unique topography of the liposomal surface barrier. Together, these attributes will result in increases, and even dramatic increase, in liposome blood circulation half-life. The novel amphiphiles may also be employed as functional components of other types of drug delivery vehicles. In fact, the unique structural and physicochemical properties of the disclosed amphiphiles render them useful in various biomedical applications and for use as blood substitutes, parenteral nutritional fat emulsions, antigen-presenting vehicles in diagnostics, and in skin and other personal care consumer products.

#### Detailed Description Text (60):

Micelles are formed on hydration of novel amphiphiles designed with branched hydrophobic moieties bearing multiple lipid chains. Microemulsions are produced by homogenization of triglyceride oil and novel amphiphile in aqueous buffer. The novel orientation and topography of multiple PEG chains in novel liposomes is appropriate also for micelles and microemulsions, and indeed any lipid-bearing hydrophobic surface. The latter include the lipid bilayer membranes of biological cells. Thus a new cell surface is generated on treatment with novel amphiphile and comprises a poly-anchored PEG/polymer coat eclipsing the surface antigens. On the other hand, the poly-anchored PEG/polymer coat around a synthetic lipid assembly is most appropriate for attaching antigenic ligands for use in diagnostic test kits, and for supporting antibodies for targeting therapeutic liposomes to desired tissue cells.

#### Detailed Description Text (63):

In conventional liposomes, whether <u>multilamellar</u> vesicles (MLV) or unilamellar vesicles (ULV), the hydrated lipid bilayers are present in the <u>liquid-crystalline</u> (L.sub..alpha.) or the gel (L.sub..beta., L.sub..beta..) phases at physiological temperature depending principally on the main chain melting transition (T.sub.c) of the component lipids. The effect of polypodal amphiphiles as additional lipid components on the gross morphology and phase structure may be visualized as follows. p As a first approximation, the lipid ends in bipodal PA-PEG-PA with infinitely long PEG chain length may be regarded as two independent anionic

phospholipids. This independence is indicated also by molecular models which suggest that long PEG chain permits a high level of flexibility and conformational mobility for the terminal lipid residues. Therefore, at low molar proportions, the anionic phospholipid residues of PA-PEG-PA will get incorporated into the bilayer as is observed with phosphatidylglycerol and analogous phosphatidyl-alkylester phospholipids. Such additives cause only a minimum of perturbation of the lyotropic phase of the lipid bilayer. Statistical mixing and the repulsive influence of the head group anionic charge promote wide separation between individuals. The morphology and effects of the PEG link between the terminal phospholipids spaced far apart in the lipid bilayer can then be considered.

#### Detailed Description Text (151):

The hydrates were equilibrated by vortex mixing, repeated cycles of freezing and thawing, and incubation above the T.sub.c. Some of these preparations were examined in a polarized light microscope and these showed birefringence (myelin figures) characteristic of multilamellar bilayer structures (MLVs). The MLVs were stored at ambient temperature for 24 h. The <a href="liquid crystalline">liquid crystalline</a> phase status of these hydrates was characterized by X-ray diffraction as described in EXAMPLES 7, 8 and 9. Dilution with additional quantity of the aqueous phase followed by sonication in bath sonicator (Laboratory Supplies Co., Hicksville, N.Y.) and/or extrusion of the MLVs through 100 .mu.m pore diameter polycarbonate membranes (MacDonald et al., 1991) yielded ULVs. The ULVs were characterized and employed for encapsulation studies, e.g., of calcein as drug model in EXAMPLE 10.

#### Detailed Description Paragraph Table (5):

TABLE 4 Additional Selected Agents Oxygen Carriers Haemoglobin Perfluorinated Lipid novel amphiphiles Nutrient/Parenteral Fat emulsions Omega-3-glycerides Fat soluble vitamins Tocopherols Contrasting Agents Gadolinium complexes Barium meal Antigen presenting vehicles (Novel amphiphiles with attached ligands) Lectin RGD Immunogenic peptides Interleukins CSFs LFAs Interferons Immunoglobulins

# <u>Current US Original Classification</u> (1): 424/450

#### CLAIMS:

46. The amphiphilic molecule of claim 43, wherein said liposome further comprises at least one surface available antibody, binding ligand or <u>antigen</u> disposed in the liposome bilayer or tethered to a component of the liposome bilayer.

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Generate Collection ... Print

L5: Entry 5 of 11

File: USPT

Mar 2, 2004

US-PAT-NO: 6699499

DOCUMENT-IDENTIFIER: US 6699499 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Amphiphilic materials and liposome formulations thereof

DATE-ISSUED: March 2, 2004

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Aneja; Rajindra Ithaca NY

ASSIGNEE-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY TYPE CODE

Nutrimed Biotech Ithaca NY 02

APPL-NO: 09/879368 [PALM]
DATE FILED: June 11, 2001

#### PARENT-CASE:

The present application is a divisional application of U.S. application Ser. No. 08/912,978, filed Aug. 13, 1997, which claims priority to provisional application Ser. No. 60/024,382, filed Aug. 14, 1996, the entire text and figures of which disclosure are specifically incorporated herein by reference without disclaimer.

INT-CL-ISSUED: [07] A61K 9/127

## INT-CL-CURRENT:

TYPE IPC DATE 20060101 CIPS A61 K 8/14 CIPS <u>CO7</u> <u>F</u> <u>9/00</u> 20060101 CIPS C07 F 9/10 20060101 CIPS C08 G 65/00 20060101 CIPS <u>CO8</u> <u>G</u> <u>65/329</u> 20060101 CIPS C08 G 65/335 20060101 CIPS <u>C08</u> <u>G</u> <u>65/337</u> 20060101 CIPS A61 K 8/72 20060101 CIPS A61 K 9/127 20060101 CIPS <u>A61 K 8/86</u> 20060101 CIPS A61 Q 19/00 20060101 CIPS C11 D 17/00 20060101

US-CL-ISSUED: 424/450; 424/1.21, 424/9.321, 424/9.51, 424/417, 424/94.3, 428/402.2, 554/79, 554/80, 554/103, 554/227

US-CL-CURRENT: 424/450; 424/1.21, 424/417, 424/9.321, 424/9.51, 424/94.3, 428/402.2, 554/103, 554/227, 554/79, 554/80

FIELD-OF-CLASSIFICATION-SEARCH: 424/450, 424/1.21, 424/9.321, 424/9.51, 424/417, 424/94.3, 428/402.2, 436/829, 554/76, 554/80, 554/103, 554/227 See application file for complete search history.

PRIOR-ART-DISCLOSED:

#### U.S. PATENT DOCUMENTS

# Search Selected Search ALL Clear

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
4772471	September 1988	Vanlerberghe et al.	424/450
· <u>4830857</u>	May 1989	Handjani et al.	424/450
4837028	June 1989	Allen	424/450
4920016	April 1990	Allen et al.	424/450
5013556	May 1991	Woodle et al.	424/450
5153000	October 1992	Chikawa et al.	424/450
5225212	July 1993	Martin et al.	424/450
5395619	March 1995	Zalipsky et al.	424/450
6284267	September 2001	Aneja	

#### FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	CLASS
0370491	April 1995	EP	

## OTHER PUBLICATIONS

Allen and Chonn, "Large unilamellar liposomes with low uptake into the reticuloendothelial system," FEBS Lett., 223(1):42-46, 1987.

Allen, Hansen, Martin, Redemann, Yau-Young, "Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo," Biochim. Biophys. Acta, 1066:29-36, 1991.

Amselem, Cohen, Barenholz, "In vitro tests to predict in vivo performance of liposomal dosage forms," Chem. Phys. Lipids, 64:219-237, 1993.

Aneja, "Structural and stereochemical purity of glycerophospholipids," Biochem. Soc. Trans., 2:38-41:1974.

Aneja, "Novel biomolecular approaches to steric stabilization of liposomes: materials and organization," An American Chemical Society Symposium, ACS Annual Meeting, Sep. 8-11, Las Vegas, NV, 1977.

Aneja, "Novel biomaterials for optimizing liposomal drug delivery," 213th ACS National Meetingof the American Chemical Society, San Francisco, California, USA, Abstracts of Papers American Chemical Society, 213:(1-3), Abstract BIOT-003, Apr. 13-17, 1997.

Aneja, Chadha, Davies, "A general synthesis of glycerophospholipids," Biochim. Biophys. Acta, 218:102-111, 1970.

Aneja and Davies, "The synthesis of a spin-labelled glycero-phospholipid," Chem. Phys. Lipids, 4:60-71, 1970.

Bahr, Deppe, Karas, Hillenkamp, "Mass spectrometry of synthetic polymers by UV-matrix-assisted laser desorption/ionization," Anal. Chem., 64:2866-2869, 1992. Balch, Morris, Brooks, Sleight, "The Use of N-(7-nitrobenz-2-oxa-1,3-diazole-4-yl)-labeled lipids in determining transmembrane lipid distribution," Chem. Phys. Lipids, 70:205-212, 1994.

Banagham and Horne, "Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope," J. Mol. Biol., 8:660-668, 1964.

Bangham, Standish, Watkins, "Diffusion of univalent ions across the lamellae of swollen phospholipids," J. Mol. Biol., 13:238-252, 1965.

Bartlett, "Phosphorus assay in column chromatography," J. Biol. Chem., 234(3):466-468, Mar. 1959.

Beauchamp, Gonias, Menapace, Pizzo, "A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and .alpha..sub.2 -macroglobulin," Anal. Biochem., 131:25-33, 1983.

Blume and Cevc, "Liposomes for the sustained drug release in vivo," Biochim. Biophys. Acta, 1029:91-97, 1990.

Caffrey, "Kinetics and mechanism of the lamellar gel/lamellar liquid-crystal and lamellar/inverted hexagonal phase transition in phosphatidylethanolamine: A real-time x-ray diffreaction study using synchrotron radiation," Biochemistry, 24:4826-4844, 1985.

Caffrey and Bilderback, "Kinetics of the main phase transition of hydrated lecithin monitored by real-time x-ray diffraction," Biophys.J., 45:627-631, Mar. 1984. Chattopadhyay, "Chemistry and biology of N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-labeled lipids: fluorescent probes of biological and model membranes," Chem. Phys. Lipids, 53:1-15, 1990.

Dao, McIntyre, Sleight, "Large-scale preparation of asymmetrically labeled fluorescent lipid vesicles," Anal. Biochem., 196:46-53, 1991.

de Gennes, "Conformations of polymers attached to an interface," Macromolecules, 13:1069-1075, 1980.

Fattal, Nir, Parente, Szoka Jr., "Pore-Forming Peptides Induce Rapid Phospholipid flip-flop in membranes," Biochemistry, 33:6721-6731, 1994.

Gombotz and Pettit, "Biodegradable polymers for protein and peptide drug delivery," Bioconjugate Chem., 6:332-351, 1995.

Gregoriadis, "Fate of injected liposomes: observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo," In: Liposomes as Drug Carriers, Wiley, New York, pp. 3-18, 1988.

Griffin, "Calculation of "HLB" values of nonionic surfactants," J. Soc. Cosmetic Chemists, 1:311-326, 1949, as cited in Biological Abstracts, 27:1955, column 9941. Griffin, "Calculation of "HLB" values of nonionic surfactants," Am. Perfumer Essential Oil Rev., 65(5):26-29, 1955, as cited in Biological Abstracts, 27:1955, column 9941.

Herbette, Marquardt, Scarpa, Blasie, "A direct analysis of lamellar x-ray diffraction from hydrated oriented multilayers of fully functional sarcoplasmic reticulum," Biophys. J., 20:245-272, 1977.

Hope, Bally, Webb, Cullis, "Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential," Biochem. Biophys. Acta, 812:55-65, 1985.

Hristova and Needham, "Physical properties of polymer-grafted bilayers," In: Stealth.RTM. Liposomes, Lasic and Martin eds., CRC Press, Boca Raton, FL, Ch. 5, pp. 35-49, 1995.

Kenworthy, Hristova, Needham, McIntosh, "Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol)," Biophys. J., 68:1921-1936, May 1995.

Kenworthy, Simon, McIntosh, "Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol)," Biophys.

#### J., 68:1903-1920, 1995.

Kenworthy, Simon, McIntosh, "Effects of lipids with covalently attached polyethylene glycol on distearolyphosphatidylcholine bilayer structure," Biophysical Journal, 38th Annual Meeting of the Biophysical Society, New Orleans, Louisiana, USA, Mar. 6-10, 1994.

Klibanov, Maruyama, Beckerleg, Torchilin, Huang, "Activity of amphipathic poly (ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target," Biochim. Biophys. Acta, 1062:142-148, 1991.

Klibanov, Maruyama, Torchilin, Huang, "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes," FEBS Lett., 268(1):235-237, 1990. Kuhl, Leckband, Lasic, Israelachvili, "Modulation of interaction forces between bilayers exposing short-chained ethylene oxide headgroups," Biophys. J., 66:1479-1488, 1994.

Lasic, "Sterically stabilized vesicles," Angew. Chem. Int. Ed. Engl., 33:1685-1698, 1994.

Lasic and Barenholz, eds., "F. Liposomes in drug delivery," In: Handbook of Nonmedical Applications of Liposomes, From Gene Delivery and Diagnostics to Ecology, CRC Press, Boca Raton, FL., vol. IV, pp. 308-309, 1996.

Lasic, Martin, Gabizon, Huang, Papahadjopoulos, "Sterically stabilized liposomes \*: a hypothesis on the molecular origin of the extended circulation times," Biochim. Biophys. Acta, 1070:187-192, 1991.

Lasic, Woodle, Martin, Valentincic, "Phase behavior of >>stealth.RTM.-lipid<<-lecithin mixtures," Periodicum Biologorum, 93(2):287-290, 1991.

Lefkowitz, Stadel, Caron, "Adenylate cyclase-coupled beta-adrenergic receptors. Structure and mechanisms of activation and desensitization," Ann. Rev. Biochem., 52:159-186, 1983.

Lesieur, Grabielle-Madelmont, Paternostre, Ollivon, "Study of size distribution and stability of liposomes by high performance gel exclusion chromatography," Chem. Phys. Lipids, 64:57-82, 1993.

Liu and Huang, "Small, but not large, unilamellar liposomes composed of dioleoylphosphatidylethanolamine and oleic acid can be stabilized by human plasma," Biochemistry, 28:7700-7707, 1989.

MacDonald, MacDonald, Menco, Takeshita, Subbarao, Hu, "Small-volume extrusion apparatus for preparation of large, unilamellar vesicles," Biochem. Biophys. Acta, 1061:297-303, 1991.

Marsh, "X-ray diffraction data," In: CRC Handbook of Lipid Bilayers, CRC Press, Boca Raton, FL, Ch. II.8, pp. 163-183, 1990.

Mayer, Hope, Cullis, "Vesicles of variable sizes produced by a rapid extrusion procedure," Biochim. Biophys. Acta, 858:161-168, 1986.

McIntosh, Magid, Simon, "Steric repulsion between phosphatidylcholine bilayers," Biochem., 26:7325-7332, 1987.

Mori, Klibanov, Torchilin, Huang, "Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM.sub.1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo," FEBS Lett., 284 (2):263-266, Jun. 1991.

Navarro, Chabot, Sherrill, Aneja, Zahler, Racker, "Interaction of duramycin with artificial and natural membranes," Biochemistry, 24(17):4645-4650, 1985.

Needham, McIntosh, Lasic, "Repulsive interactions and mechanical stability of polymer-grafted lipid membranes," Biochim. Biophys. Acta, 1108:40-48, 1992.

Neugebauer, "Detergents: an overview," Methods in Enzymology, 182:239-252, 1990.

Nishikawa, Arai, Inoue, "Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages," J. Biol. Chem., 265(9):5226-5231, Mar. 25, 1990.

Nolan, Magargee, Posner, Hammerstedt, "Flow cytometric analysis of transmembrane phospholipid movement in bull sperm," Biochemistry, 34:3907-3915, 1995.

Parr, Ansell, Choi, Cullis, "Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles," Biochim. Biophys. Acta, 1195:21-30, 1994.

Parsegian, Rand, Fuller, Rau, "Osmotic stress for the direct measurement of

intermolecular forces, " Methods Enzymol., 127:400-416, 1986.

Rand and Luzzati, "X-ray diffraction study in water of lipids extracted from human erythrocytes," Biophys. J., 8:125-137, 1968.

Small, "Polar lipids," In: Handbook of Lipid Research, The Physical Chemistry of Lipids, From Alkanes to Phospholipids, Plenum Press, New York, Ch. 4, p. 93, 1986a.

Small, "Phospholipids," In: Handbook of Lipid Research, The Physical Chemistry of Lipids, From Alkanes to Phospholipids, Plenum Press, New York, Ch. 12, pp. 475-522, 1986b.

Szoka, Olson, Heath, Vail, Mayhew, Papahadjopoulos, "Preparation of unilamellar liposomes of intermediate size (0.1-0.2.mu.m) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes," Biochim. Biophys. Acta, 601:559-571, 1980.

Szoka Jr. and Papahadjopoulos, "Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation," Proc. Natl. Acad. Sci. U.S.A., 75(9):4194-4198, Sep. 1978.

Winterhalter and Lasic, "Liposome stability and formation: Experimental parameters and theories on the size distribution," Chem. Physics Lipids, 64:35-43, 1993. Woodle, "Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation," Chem. Physics Lipids, 64:249-262, 1993.

Woodle and Lasic, "Sterically stabilized liposomes," Biochim. Biophys. Acta, 1113:171-199, 1992.

Woodle, Engbers, Zalipsky, "New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes," Bioconjugate Chem., 5 (6):493-496, 1994.

Woodle, Matthay, Newman, Hidayat, Collins, Redemann, Martin, Papahadjopoulos, "Versatility in lipid compositions showing prolonged circulation with sterically stablized liposomes," Biochim. Biophys. Acta, 1105:193-200, 1992.

Worthington, "The interpretation of low-angle x-ray data from planar and <u>concentric</u> multilayered structures. The use of one-dimensional electron density strip models," Biophys. J., 9:222-234, 1969.

Yatvin, Tegmo-Larsson, Dennis, "Temperature- and pH-sensitive liposomes for drug targeting," Methods in Enzymology, 149:77-87, 1987.

Zalipsky, "Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates," Bioconjugate Chem., 6:150-165, 1995.

ART-UNIT: 1615

PRIMARY-EXAMINER: Kishore; Gollamudi S.

ATTY-AGENT-FIRM: Williams, Morgan and Amerson

#### ABSTRACT:

Disclosed is a new structural class of amphiphilic molecules which incorporate a hydrophilic material or polymer attached, at spatially distinct sites, to at least two hydrophobic residues. Certain of the amphiphilic molecules comprise a plurality of hydrophobic moieties. All such amphiphilic molecules have a common structural motif and, in contact with water, display surface activity and self-assemble into multimolecular aggregates and liquid crystalline phases. Also disclosed are enhanced stability liposomes that incorporate such amphiphilic molecules via unique interactions, and methods of using such formulations in a variety of applications including drug delivery, nutrition, bio-diagnostics, cosmetics, blood products and related applications.

45 Claims, 10 Drawing figures

First Hit Fwd Refs

Previous Doc

Next Doc

Go to Doc#

**End of Result Set** 

Generate Collection Print

L1: Entry 1 of 1

File: USPT

Dec 5, 2000

DOCUMENT-IDENTIFIER: US 6156337 A

TITLE: Method for high loading of vesicles with biopolymeric substances

## <u>Drawing Description Text</u> (43):

The selection of phospholipids for the lipsomal <u>vaccine</u> preparation is based on two main parameters: (i) chemical stability; (ii) uptake by macrophages. Surprisingly, the selection of dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG) as the raw material for liposome preparation was advantageous. These disaturated phospholipids are not susceptible to various oxidation processes. Their gel to <u>liquid crystalline</u> phase transition (T.sub.m) is 24.degree. C., and therefore at 37.degree. C. the lipids are in their <u>liquid crystalline</u> state, which is preferred for uptake by macrophages. The negative charge introduced by the DMPG also increases liposome uptake by macrophages which serve as antigene presenting cells. Large liposomes (<u>multilamellar large vesicles</u>) are advantagaeous due to their preferred uptake by the macrophages.

Previous Doc

Next Doc

Go to Doc#